Oxford BioTheraputics Names Abderrahim Fandi as CMO
Abderrahim Fandi, formerly of Celgene, has joined Oxford BioTherapeutics as the company’s CMO. His position will be responsible for developing OBT’s immuno-oncology candidates. “Rahim brings a wealth of drug development expertise to OBT, which will significantly benefit the company as we move our clinical development program forward in the United States for MEN1309, our novel…
This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.
Key takeaways
Abderrahim Fandi, formerly of Celgene, has joined Oxford BioTherapeutics as the company’s CMO.
His position will be responsible for developing OBT’s immuno-oncology candidates.
“Rahim brings a wealth of drug development expertise to OBT, which will significantly benefit the company as we move our clinical development program forward in the United States for MEN1309, our novel…
Free workspace
Turn your Sciences expertise into content.
Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.
Abderrahim Fandi, formerly of Celgene, has joined Oxford BioTherapeutics as the company’s CMO. His position will be responsible for developing OBT’s immuno-oncology candidates.
“Rahim brings a wealth of drug development expertise to OBT, which will significantly benefit the company as we move our clinical development program forward in the United States for MEN1309, our novel ADC therapy [that’s] currently undergoing clinical testing in Europe,” said OBT CEO Christian Rohlff in a recent statement.[1]
The press release announces that Dr. Fandi has led the development of several oncology compounds and participated in successful regulatory interactions, including many with the FDA. He has also held positions at Novartis, BMS, AstraZeneca, and Sanofi Aventis, and has contributed to over 100 peer-reviewed publications and abstracts. In addition, he has served as first author in lead journals, including the Journal of Clinical Oncology.
To read the full press release from Oxford BioTherapeutics, visit PharmiWeb.com.
[1] https://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=267248
Your experts belong here
Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.
Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.
About the author
